Influence of Intervention Methodologies on Patient Choice of Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

248 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Few studies have explored how specific formats of effectiveness information effect on real patients' decisions. We only know little about what kind of format would be the optimal to help patients make well-informed real-life decisions corresponding to their preferences.

The trial is developed in a clinical randomised design to study risk communication in the shared decision making between general practitioners (GP) and their patients in primary prevention with of cholesterol lowering drug. Endpoints are effect of GPs' information about treatment effectiveness and their patients' values on patients' tendency to accept and adhere to the treatment as well as their feeling of content with the choice made. GPs are randomised to inform about risk and treatment effectiveness by means of either absolute risk reduction (ARR) or Prolongation of Life (POL). Afterwards patients are invited to answer questionnaires concerning their content with decisions and reflections. Patients' redemption of prescriptions during the following week and the first year are recorded through an electronic database.

57 GPs and 248 patients have been enrolled in the trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Shared Decision-making: Effects on Cardiac Risk Factor Modification Behavior

NCT00714935

Coronary Artery Disease Decision Making

COMPLETED NA

The Impact of Patient Involvement in Decision-Making About Heart Disease Prevention

NCT00315978

Cardiovascular Disease

COMPLETED NA

Impact of a Decision Aid Regarding Natural Health Products for Menopausal Symptoms

NCT00325923

Decision Making Choice Behavior Decision Support Techniques +1 more

COMPLETED NA

Focus on Values to Stimulate Shared Decisions

NCT03905369

Thyroid Cancer

UNKNOWN NA

Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AFib Stroke Prevention

NCT04096781

Atrial Fibrillation Atrial Flutter Stroke +3 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As chronic diseases are steadily increasing in the industrialized countries, there is a growing focus on preventive initiatives. This means that risk communication between the physician and his patients plays a central role.

Effective risk communication can enhance knowledge, involvement in decisions about tests or treatment, autonomy and empowerment of patients. Poor communication, however, can lead to anxiety, lack of confidence in health care professionals, and other adverse outcomes. It is vital that we identify the available evidence about how it should best be done.

The standard formats used to communicate intervention effectiveness are absolute risk reduction, relative risk reduction, number needed to treat, and life prolongation of life.

Few studies have explored the formats' influence on real patient decisions, implying that we only know little about what kind of format would be the optimal to help patients make well-informed real-life decisions corresponding to their preferences.

In a clinical randomized design risk communication is studied in the preventive talk between the general practitioner (GP) and his patients concerning cardiovascular diseases. Special focus is on influence of information format on patients' choice of therapy, adherence to therapy and satisfaction with therapy.

GPs are randomized to one of two groups, being taught in informing their patients by means of either absolute risk reduction, ARR or life extension, LE.

The setting is the preventive talk in the GP's clinic. From a measured total-cholesterol the GP informs his patient about the individual risk of getting a cardiovascular disease and the possible effectiveness of a cholesterol-lowering drug. This is done by means of either ARR or LE. After the talk the patient is invited to answer a questionnaire concerning personal experience with the information given (deadline 2 weeks after the talk), and again after 3 months will receive a questionnaire concerning satisfaction with the decision made and reflections. Patients' redemption of prescriptions during the following week and the first year are recorded through Odense PharmacoEpidemiological Database, OPED. The GPs' opinions, experiences and concerns about risk communication, prevention, and usage of statins are explored by means of questionnaires.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Communication Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Absolute risk reduction information

Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.

Group Type ACTIVE_COMPARATOR

Absolute risk reduction

Intervention Type BEHAVIORAL

Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction

Prolongation of life information

Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.

Group Type ACTIVE_COMPARATOR

Prolongation of life

Intervention Type BEHAVIORAL

Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Absolute risk reduction

Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction

Intervention Type BEHAVIORAL

Prolongation of life

Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ARR POL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 40-69 year-olds
* Patients with a measured total-cholesterol of \> 4 MMol/Litre

Exclusion Criteria

* Patients with diabetes
* Patients with known chronic cardiovascular diseases
* Patients who are already being treated with cholesterol lowering therapy
* Patients who are not familiar with the danish language

Minimum Eligible Age

40 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No